Navigation Links
Researchers Report Treatment Headway Against Lung Cancer
Date:6/5/2010

Studies show combo chemotherapy, new drug prolonged lives of some with advanced disease

SATURDAY, June 5 (HealthDay News) -- Researchers report they prolonged survival for some patients with advanced non-small cell lung cancer, for whom the median survival is currently only about six months.

One study discovered that an experimental drug called crizotinib shrank tumors in the majority of lung cancer patients with a specific gene variant. An estimated 5 percent of lung cancer patients, or roughly 40,000 people worldwide, have this gene variant.

A second study found that a double-chemotherapy regimen benefited elderly patients, who represent the majority of those with lung cancer worldwide. Roughly 100,000 patients with lung cancer in the United States are over the age of 70.

"This is our toughest cancer in many ways," said Dr. Mark Kris, moderator of a Saturday press conference at the annual meeting of the American Society of Clinical Oncology (ASCO), in Chicago. "It affects 220,000 Americans each year, and over a million people worldwide. Sadly, it is our nation's -- and our world's -- leading cancer."

The first study, a phase 1 trial, found that 87 percent of 82 patients with advanced non-small cell lung cancer with a specific mutation of the ALK gene, which makes that gene fuse with another, responded robustly to treatment with crizotinib, which is made by Pfizer Inc.

"The patients were treated for an average of six months, and more than 90 percent saw their tumors shrink in size and 72 percent of participants remained progression-free six months after treatment," said study author Dr. Yung-Jue Bang, a professor in the department of internal medicine at Seoul National University College of Medicine in South Korea. Ordinarily, only about 10 percent of patients would be expected to respond to treatment.

About half of patients experienced nausea, vomiting and diarrhea but these side effects eased over time, Bang said.

The fusion gene was first discovered to play a role in this type of lung cancer in 2007. Researchers are now working on a phase 3 trial of the drug. The Korean researchers reported financial ties to Pfizer.

The second study, a phase 3 trial, involved 451 patients with advanced non-small cell lung cancer aged 70 to 89. The study had first expected to enroll 520 patients, but it was halted early when good survival results were seen in the group taking the combination therapy.

Currently, elderly patients are typically given just one chemotherapy drug, with younger patients more likely to get two or more.

In this trial, participants were randomly selected to receive either one chemotherapy agent -- gemcitabine (Gemzar) or vinorelbine (Navelbine) -- or to receive both carboplatin and paclitaxel (Taxol).

For the single-agent group, median survival at one year was 6.2 months and 27 percent patients were still alive, "which is consistent with previous research," said study author Dr. Elisabeth Quoix, a professor of medicine at University Hospital in Strasbourg, France.

"In the double-therapy group, the median survival increased by four months [to 10.3 months], which is quite unusual in thoracic oncology," Quoix said. "Forty-five percent of patients survived one year, which is also quite unusual."

"The four-month improvement is a huge one," added Kris, who is chief of thoracic oncology at Memorial Sloan-Kettering Cancer Center in New York City. "Other large clinical trials ... have generally felt to be practice-changing with a two-month change in median survival. This trial supports the idea that patients over 70 should be treated just as anyone else."

Quoix and other study authors reported ties with different pharmaceutical companies, including Eli Lilly Co. and Roche Inc.

Finally, a phase 3 study out of the University of Texas M.D. Anderson Cancer Center in Houston found patients receiving the targeted drug vandetanib combined with chemotherapy had a 21 percent decline in disease progression compared to those receiving chemotherapy alone. Median progression-free survival in the combination arm was 17.3 weeks vs. 14 weeks in the control group.

This study was simultaneously presented Saturday at the ASCO meeting and published in The Lancet Oncology.

Kris also reported ties with several pharmaceutical firms.

More information

The U.S. National Cancer Institute has more on lung cancer.



SOURCES: June 5, 2010, teleconference with Mark G. Kris, M.D., chief, thoracic oncology service, Memorial Sloan-Kettering Cancer Center, New York City; Elisabeth Quoix, M.D., professor, medicine, University Hospital, Strasbourg, France; Yung-Jue Bang, M.D., Ph.D., professor, department of internal medicine, Seoul National University College of Medicine, Seoul, South Korea; June 5, 2010, presentations, American Society of Clinical Oncology annual meeting, Chicago; June 5, 2010, The Lancet Oncology, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. MSU researchers discover potential genetic factor in eating disorders
2. Mount Sinai researchers approaching universal treatment for all strains of influenza
3. Leading physicians and researchers at the John Theurer Cancer Center present research at ASCO
4. Basque researchers apply chemistry to restoration of paintings and dating of signatures
5. Researchers offer solutions to poisonous well-water crisis in southern Asia
6. Researchers report no difference in breast cancer characteristics after oophorectomy
7. Vanderbilt researchers play major role in new center on electronic health information privacy
8. Pitt researchers discover gene mutation linked to lymphatic dysfunction
9. Researchers validate a new test for assessing childrens and teenagers fitness to prevent morbidity
10. Novel anti-malarial drug candidate found by UT Southwestern researchers
11. Mount Sinai researchers move closer to a universal influenza vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and ... women in the world, and the most handsome men, look naturally attractive. Plastic ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... SYDNEY , June 26, 2016 One of ... , has announced the formation of a new biotechnology company, Noxopharm ... raise $6m in an IPO and to list on the ASX. ... drug candidate, NOX66, ready to enter a Phase 1 clinical study ... been designed to address one of the biggest problems facing cancer ...
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
Breaking Medicine Technology: